Aaron Mestemaker
Nurse Practitioner · Grand Rapids, MINPI 1407631104
Payments from drug & device makers
Across 137 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$341
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$192
- Amgen$178
- Boehringer Ingelheim$175
- Bayer$157
- Novo Nordisk$153
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,224100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 25 | $341 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $192 |
| Amgen | 9 | $178 |
| Boehringer Ingelheim | 7 | $175 |
| Bayer | 8 | $157 |
| Novo Nordisk | 8 | $153 |
| E.r. Squibb & Sons, L.L.C. | 9 | $152 |
| Merck | 5 | $95 |
| Boston Scientific | 4 | $89 |
| Lexicon Pharmaceuticals, Inc. | 5 | $88 |
| Impulse Dynamics (USA) Inc. | 3 | $62 |
| Pfizer | 3 | $62 |
| Alnylam Pharmaceuticals Inc. | 3 | $57 |
| Abiomed | 3 | $56 |
| AstraZeneca | 3 | $53 |
| Biotronik Inc. | 2 | $48 |
| Scpharmaceuticals Inc. | 3 | $46 |
| Actelion Pharmaceuticals US, Inc. | 2 | $40 |
| Lilly USA, LLC | 2 | $39 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Medtronic | 1 | $24 |
| Corcept Therapeutics | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Bridgebio Pharma, Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
How this compares
$2,224 in reported general payments places this provider in the 90th percentile of 3,351 nurse practitioner providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 126 | $167,237 |
| EntrestoSacubitril/Valsartan | 60 | $75,872 |
| XareltoRivaroxaban | 40 | $44,810 |
| Repatha SureclickEvolocumab | 39 | $34,346 |
| JardianceEmpagliflozin | 20 | $26,803 |
| FarxigaDapagliflozin Propanediol | 28 | $24,871 |
| BrilintaTicagrelor | 35 | $24,175 |
| Metoprolol Succinate | 338 | $7,975 |
| Ezetimibe | 121 | $4,759 |
| Rosuvastatin Calcium | 170 | $3,878 |
| Dofetilide | 17 | $3,647 |
| Losartan Potassium | 156 | $2,531 |
| Atorvastatin Calcium | 129 | $2,489 |
| Ranolazine ErRanolazine | 27 | $2,186 |
| Amlodipine Besylate | 171 | $1,776 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $62 | $167,237126 claims |
| NovartisEntresto | $341 | $75,87260 claims |
| AstraZenecaFarxiga, Brilinta | $53 | $49,04763 claims |
| Boehringer IngelheimJardiance | $175 | $26,80320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,351 nurse practitioner providers in Michigan.
Other nurse practitioner in Grand Rapids
- Debra DegraffGrand Rapids$80K
- Aaron EmmonsGrand Rapids$29K
- Natasha PeoplesGrand Rapids$12K
- Davida KrugerDetroit$1.8M
- Kari HillSpring Lake$426K
- Kyle FarrPlymouth$243K
- Linda SpencerTroy$217K
- Ellen DillardDetroit$168K
- Golbon AghamohammadiDetroit$157K
- Abubakir BabanDearborn$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.